ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY

Diğer sürümleri göster (1)

Detaylı Bibliyografya
Asıl Yazarlar:	Griesenbach, U, Inoue, M, Meng, C, Farley, R, Chan, M, Newman, N, Brum, A, You, J, Kerton, A, Shoemark, A, Boyd, A, Davies, J, Higgins, T, Gill, DR, Hyde, S, Innes, J, Porteous, D, Hasegawa, M, Alton, E
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	2012

Benzer Materyaller

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Towards a first-in-human trial with a pseudotyped lentivirus
Yazar:: Alton, EW, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
Yazar:: Hyde, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
Yazar:: Sergijenko, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
Yazar:: Pytel, K, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
Yazar:: Davies, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
Yazar:: Davies, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

A Functional <it>Henipavirus </it>Envelope Glycoprotein Pseudotyped Lentivirus Assay System
Yazar:: Broder Christopher C, ve diğerleri
Baskı/Yayın Bilgisi: (2010-11-01)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
Yazar:: Palau, H, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Self-reactive CFTR T cells in humans: implications for gene therapy.
Yazar:: Calcedo, R, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
Yazar:: Lund-Palau, H, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Lentiviral vector pseudotyped with sendai virus F and HN proteins uses sialylated glycan receptors to efficiently target human airway cells
Yazar:: Munday, RJ, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

F/HN pseudotyped lentiviral vector uses alpha 2,3 sialylated N-acetyllactosamine to efficiently transduce human airway cells
Yazar:: Munday, RJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Genetic medicines for CF: Hype versus reality
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
Yazar:: Rosie J. Munday, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
Yazar:: Lund-Palau, H, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
Yazar:: Munday, RJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Eucalyptus Essential Oil Inhibits Cell Infection by SARS-CoV-2 Spike Pseudotyped Lentivirus
Yazar:: Sara Alonso Fernandez, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
Yazar:: Griesenbach, U, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Assessment of the air-liquid interface culture model as a tool to validate efficacy of a rSIV.F/HN-CFTR vector
Yazar:: Sergijenko, A, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Transgenesis and Genome Editing of Mouse Spermatogonial Stem Cells by Lentivirus Pseudotyped with Sendai Virus F Protein
Yazar:: Takashi Shinohara, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
Yazar:: Alton, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles
Yazar:: Ian Helstrup Nielsen, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
Yazar:: Gélinas, J, ve diğerleri
Baskı/Yayın Bilgisi: (2017)